ESTIMATION OF SIMVASTATIN AND EZETIMIBE BY USING HPTLC METHOD
A high-performance thin-layer chromatographic method has been developed and validated for the estimation of Simvastatin and ezetimibe simultaneously in combined dosage forms. The stationary phase used was pre-coated silica gel 60F 254. The mobile phase used was a mixture of Benzene: methanol: Acetone: Triethylamine (7.2:1:0.4 v/v/v/v). The detection of spots was carried out at 266 nm. The method was validated in terms of linearity, accuracy, precision and specificity. The calibration curve was found to be linear between 0.8 and 4.0 µg/spot for Simvastatin and 0.1 and 1.0 µg/spot for ezetimibe. The limit of detection and the limit of quantification for Simvastatin were found to be 160 ng/spot and 560 ng/spot respectively, and for ezetimibe, 30 ng/spot and 80 ng/spot respectively. The proposed method can be successfully used to determine the drug content of marketed formulation.